Scandinavian ChemoTech AB (publ) Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Scandinavian ChemoTech AB (publ) Stock Forecast and Price Target
The average target price set lately by experts for Scandinavian ChemoTech AB (publ) to reach by the end of the year is kr2.60, which would imply a potential upside of approximately 20.93 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of kr2.60 and a low estimate of kr2.60. If you're looking for information on Scandinavian ChemoTech AB (publ) stock, consider checking out the forecasts for comparable firms such as NGM:SYNT.
20.93% Upside
Scandinavian ChemoTech AB (publ) Fair Value Forecast for 2023 - 2025 - 2030
Scandinavian ChemoTech AB (publ)'s Price has seen growth In the last two years, going from kr0.00 to kr0.00 – a gain of 100.00% In the next year, analysts believe that Fair Value will reach kr2.28 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GETI B Stock Forecast | Getinge AB | Outperform |
18
|
kr232.30 | Buy/Sell | kr226.10 | -1.85% |
| EKTA B Stock Forecast | Elekta AB (publ) | Hold |
18
|
kr76.95 | Buy/Sell | kr83.00 | 1.36% |
| ALIF B Stock Forecast | AddLife AB (publ) | Buy |
18
|
kr102.00 | Buy/Sell | kr111.00 | 34.31% |
| SUS Stock Forecast | Surgical Science Sweden AB (pu... | Outperform |
14
|
kr154.10 | Buy/Sell | kr230.33 | 46.01% |
| CEVI Stock Forecast | CellaVision AB (publ) | Outperform |
16
|
kr226.50 | Buy/Sell | kr191.75 | 8.17% |
Scandinavian ChemoTech AB (publ) Revenue Forecast for 2023 - 2025 - 2030
Scandinavian ChemoTech AB (publ)'s Revenue has seen growth In the last three years, going from kr1.41M to kr2.82M – a gain of 100.00% In the next year, analysts believe that Revenue will reach kr5.85M – an increase of 107.39%. For the next seven years, the forecast is forRevenue to grow by 176.53%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BICO Stock Forecast | BICO Group AB (publ) | Buy |
7
|
kr46.36 | Buy/Sell | kr135.00 | 185.81% |
| HANDI Stock Forecast | Handicare Group AB (publ) | - |
16
|
kr0.00 | Buy/Sell | kr4.92 | 0.00% |
| CRAD B Stock Forecast | C-Rad AB (publ) | Outperform |
11
|
kr37.80 | Buy/Sell | kr65.50 | 53.44% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SYNT Stock Forecast | SyntheticMR AB (publ) | Outperform |
14
|
kr27.70 | Buy/Sell | kr30.00 | 8.30% |
| MNTC Stock Forecast | Mentice AB (publ) | Outperform |
6
|
kr31.70 | Buy/Sell | kr67.17 | 73.50% |
| SEZI Stock Forecast | Senzime AB (publ) |
6
|
kr7.34 | Buy/Sell | kr13.50 | 83.92% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PAX Stock Forecast | Paxman AB (publ) |
8
|
kr36.90 | Buy/Sell | kr84.00 | 116.80% | |
| SPEC Stock Forecast | SpectraCure AB (publ) | - |
0
|
kr2.80 | Buy/Sell | kr0.00 | -100.00% |
| QLINEA Stock Forecast | Q-linea AB (publ) |
6
|
kr2.46 | Buy/Sell | kr10.00 | 245.53% |
Scandinavian ChemoTech AB (publ) EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Scandinavian ChemoTech AB (publ)'s EBITDA has increased by 63.05%, going from kr-10.77M to kr-17.56M. The next year, 1 experts forecast that Scandinavian ChemoTech AB (publ)'s EBITDA will decrease by 14.01%, reaching kr-15.10M. In 2030, professionals predict that Scandinavian ChemoTech AB (publ)'s EBITDA will decrease by 28.81%, reaching kr-12.50M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LUMITO Stock Forecast | Lumito AB (publ) | - |
0
|
kr1.75 | Buy/Sell | kr0.00 | -100.00% |
| ACARIX Stock Forecast | Acarix AB (publ) |
0
|
kr0.26 | Buy/Sell | kr0.65 | 130.77% | |
| MEDF Stock Forecast | Medfield Diagnostics AB (publ) | - |
0
|
kr0.29 | Buy/Sell | kr0.00 | -100.00% |
Scandinavian ChemoTech AB (publ) EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Scandinavian ChemoTech AB (publ)'s EBIT has grown, increasing from kr-10.83M to kr-20.24M – an increase of 86.89%. According to the 1 analysts polled, in the next year, Scandinavian ChemoTech AB (publ)'s EBIT will fall by 10.57%, reaching kr-18.10M. By 2030, professionals believe that Scandinavian ChemoTech AB (publ)'s EBIT will have decreased by 24.63%, falling to kr-15.26M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OM:IRRAS Stock Forecast | IRRAS AB (publ) |
0
|
kr0.16 | Buy/Sell | kr2.58 | 3025.00% | |
| CMH Stock Forecast | Chordate Medical Holding AB (p... | - |
0
|
kr0.10 | Buy/Sell | kr0.00 | -100.00% |
| ARCOMA Stock Forecast | Arcoma AB |
0
|
kr13.10 | Buy/Sell | kr12.50 | 14.50% |
Scandinavian ChemoTech AB (publ) EPS Price Prediction Forecast for 2023 - 2025 - 2030
Scandinavian ChemoTech AB (publ)'s EPS has seen growth In the last two years, going from kr-2.05 to kr0.00 – a gain of 100.00% In the next year, analysts believe that EPS will reach kr-0.70 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REDS Stock Forecast | Redsense Medical AB (publ) | - |
-10
|
kr5.46 | Buy/Sell | kr0.00 | -100.00% |
| RNBS Stock Forecast | RNB Retail and Brands AB (publ... | - |
0
|
kr49.00 | Buy/Sell | kr250.00 | -100.00% |
| CLS B Stock Forecast | Clinical Laserthermia Systems ... |
0
|
kr16.25 | Buy/Sell | kr0.40 | 226.15% |
Site Navigation
.jpg)